Evidence map›Paper›PMID 31938097›Full record

ArticleInternational journal of clinical and experimental pathology2018

Tumor suppressor BLU exerts growth inhibition by blocking ERK signaling and disrupting cell cycle progression through RAS pathway interference.

Xiangning Zhang, Song-Jun Shao, Jia-Hui Zhou, Xiao-Wu Li, Biying Zheng, Zunnan Huang, Zhiwei He

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Xiangning ZhangDepartment of Pathophysiology, Chinese American Collaborative Cancer Research Institute, Guangdong Provincial Key Laboratory of Molecular Diagnostics, Guangdong Medical University Dongguan, Guangdong, People's Republic of China.
Song-Jun ShaoDepartment of Respiratory and Critical Medicine, Guizhou Provincial People's Hospital and Guizhou Medical University Guiyang, Guizhou, People's Republic of China.
Jia-Hui ZhouDepartment of Pathophysiology, Chinese American Collaborative Cancer Research Institute, Guangdong Provincial Key Laboratory of Molecular Diagnostics, Guangdong Medical University Dongguan, Guangdong, People's Republic of China.
Xiao-Wu LiDepartment of General Surgery, Guangdong Provincial People's Hospital, Southern Medical University Guangzhou, Guangdong, People's Republic of China.
Biying ZhengDepartment of Microbiology, Guangdong Medical University Dongguan, Guangdong, People's Republic of China.
Zunnan HuangDepartment of Pathophysiology, Chinese American Collaborative Cancer Research Institute, Guangdong Provincial Key Laboratory of Molecular Diagnostics, Guangdong Medical University Dongguan, Guangdong, People's Republic of China.
Zhiwei HeDepartment of Pathophysiology, Chinese American Collaborative Cancer Research Institute, Guangdong Provincial Key Laboratory of Molecular Diagnostics, Guangdong Medical University Dongguan, Guangdong, People's Republic of China.
Guangdong Medical College · CNGuangdong Provincial People's Hospital · CNGuiyang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have previously reported that the 3p21 tumor suppressor

Indexed as

BLU/ZMYND10cell cyclecyclin B1cyclin D1H-RASMAPK/ERK

Identifiers

PMID31938097
PMCPMC6957978
OpenAlexW3026962403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.